



European Medicines Agency

Doc. Ref.: EMEA/575732/2007
P/3/2007

EUROPEAN MEDICINES AGENCY DECISION

of 11 December 2007

**on the application for a product specific waiver for Atacand Plus and associated names,
Candesartan/Hydrochlorothiazide (EMEA-000030-PIP01-07)
in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the
Council as amended**

(ONLY THE ENGLISH TEXT IS AUTHENTIC)

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK

Tel. (44-20) 74 18 84 00 Fax (44 20) 74 18 84 16

E-mail: mail@emea.europa.eu <http://www.emea.europa.eu>

EUROPEAN MEDICINES AGENCY DECISION

of 11 December 2007

**on the application for a product specific waiver for Atacand Plus and associated names,
Candesartan/Hydrochlorothiazide (EMEA-000030-PIP01-07)
in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the
Council as amended**

THE EUROPEAN MEDICINES AGENCY,

Having regard to the Treaty establishing the European Community,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use as amended and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the application submitted by AstraZeneca AB on 2 July 2007 under Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, formulated on 26 October 2007 in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended,

Having regard to Article 25 of Regulation (EC) No 1901/2006 as amended,

WHEREAS:

- (1) The Paediatric Committee has given a positive opinion,
- (2) It is therefore appropriate to adopt a Decision granting a waiver.

HAS ADOPTED THIS DECISION:

¹ OJ L 378, 27.12.2006, p. 1

² OJ L 136, 30.4.2004, p. 1

Article 1

A waiver for Atacand Plus and associated names, Candesartan/Hydrochlorothiazide, tablet, oral use, in essential Hypertension, the details of which are set out in the Opinion of the Paediatric Committee the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to AstraZeneca AB, 15185 Södertälje, Sweden.

Done at London, 11 December 2007

For the European Medicines Agency
Thomas Lönngren
Executive Director

Signature: (On file)



European Medicines Agency
Pre-authorisation Evaluation of Medicines for Human Use

EMA/575732/2007
EMA-000030-PIP01-07

POSITIVE OPINION OF THE PAEDIATRIC COMMITTEE ON A PRODUCT-SPECIFIC WAIVER

Scope of the application

Active substance: **Candesartan/Hydrochlorothiazide**

Invented name:

Atacand Plus and associated names

Condition(s):

Essential hypertension

Pharmaceutical form(s):

Tablet

Route(s) of administration:

Oral use

Name/corporate name of the waiver applicant:

AstraZeneca AB

Information about the authorised medicinal product: see Annex I

Basis for opinion

Pursuant to Article 13(1) of Regulation (EC) No 1901/2006 of 12 December 2006, as amended, AstraZeneca AB submitted for agreement to the EMA on 02/07/2007 an application for a waiver pursuant to Article 11(1) of Regulation (EC) No 1901/2006, as amended for the above mentioned medicinal product.

The procedure started on 30 August 2007.

Opinion

The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006, as amended, recommends as set out in the appended summary report, to grant a waiver for all subsets of the paediatric population for the above mentioned condition in accordance with

Article 11(1)(c) of Regulation (EC) No 1901/2006, as amended, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

7 Westferry Circus, Canary Wharf, London, E14 4HB, UK

Tel. (44-20) 74 18 84 00 Fax (44 20) 74 18 84 16

E-mail: mail@emea.europa.eu <http://www.emea.europa.eu>

This opinion is forwarded to the applicant and the Executive Director of the Agency, together with its annex and appendix.

London, 26 October 2007

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman

Signature: (On file)

ANNEX I

INFORMATION ABOUT THE AUTHORISED MEDICINAL PRODUCT

<u>Invented name</u>	<u>Strength</u>	<u>Pharmaceutical Form</u>	<u>Route of administration</u>
Atacand Plus and associated name (including Ratacand Plus, Atacand Plus mite, Atacand Zid, Atazid, Hytacand, Hytacand Pl)	8/12.5 mg 16/12.5 mg	Tablet	oral use